Bank of America
BHVN

Bank of America’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Bank of America’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-45,000
Closed -$6.56M – 8633
2022
Q2 		$6.56M Buy
+45,000
New +$5.75M ﹤0.01% 3105
2021
Q1 		– Sell
-500
Closed -$43K – 8106
2020
Q4 		$43K Hold
500
– – ﹤0.01% 6383
2020
Q3 		$33K Hold
500
– – ﹤0.01% 6167
2020
Q2 		$37K Buy
+500
New +$26.6K ﹤0.01% 6102
2020
Q1 		– Sell
-22,000
Closed -$1.2M – 7635
2019
Q4 		$1.2M Sell
22,000
-54,500
-71% -$2.7M ﹤0.01% 4375
2019
Q3 		$3.19M Buy
76,500
+42,900
+128% +$1.81M ﹤0.01% 3626
2019
Q2 		$1.47M Sell
33,600
-10,000
-23% -$564K ﹤0.01% 4284
2019
Q1 		$2.24M Buy
+43,600
New +$1.88M ﹤0.01% 3892

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Bank of America's BHVN Position: Q4 2022 in Review

Bank of America sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 427,832 shares — an estimated $64.7M sold.

Bank of America first reported a position in BHVN in Q2 2017 and held it in 22 quarters. The position peaked at $64.7M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Bank of America reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Bank of America sold 427,832 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $64.7M.
  • Bank of America first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 22 quarters.
  • Bank of America's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $64.7M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Bank of America's 13F filing for Q4 2022, filed 10 Feb 2023.